Novo Nordisk A/S (NVO) – What Are Analysts Thinking About This Stock?

Posted by Geri Gentry on Oct 27th, 2026

Novo Nordisk A/S (NYSE:NVO – Get Free Report) has received an average rating of “Hold” from the twenty-six analysts that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a sell recommendation, sixteen have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $59.44.

A number of analysts recently weighed in on NVO shares. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, September 29th. UBS Group reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. DZ Bank restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. Finally, Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th.

Check Out Our Latest Research Report on NVO

Institutional Trading of Novo Nordisk A/S

A number of hedge funds have recently bought and sold shares of NVO. Arrowstreet Capital Limited Partnership bought a new stake in Novo Nordisk A/S during the 1st quarter valued at $287,660,000. State Street Corp raised its position in shares of Novo Nordisk A/S by 0.6% in the 2nd quarter. State Street Corp now owns 5,869,834 shares of the company’s stock worth $284,565,000 after acquiring an additional 32,641 shares in the last quarter. Royal Bank of Canada raised its position in shares of Novo Nordisk A/S by 3.2% in the 1st quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock worth $166,396,000 after acquiring an additional 141,376 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Novo Nordisk A/S by 1.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock worth $193,250,000 after acquiring an additional 71,684 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Novo Nordisk A/S by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock worth $124,844,000 after purchasing an additional 213,443 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $39.12 on Tuesday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The stock has a market capitalization of $174.67 billion, a price-to-earnings ratio of 9.56, a P/E/G ratio of 1.33 and a beta of 0.76. The stock has a fifty day simple moving average of $41.91 and a two-hundred day simple moving average of $44.81. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. On average, analysts predict that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were paid a $0.5786 dividend. This represents a yield of 258.0%. This is a negative change from Novo Nordisk A/S’s previous dividend of $1.2751. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S’s payout ratio is presently 20.05%.

About Novo Nordisk A/S

(Get Free Report)

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.